Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Identifieur interne : 003C20 ( PubMed/Corpus ); précédent : 003C19; suivant : 003C21Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Auteurs : Matthias Büchler ; Steve Chadban ; Edward Cole ; Karsten Midtvedt ; Eric Thervet ; Hans Prestele ; Paul KeownSource :
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [ 0931-0509 ] ; 2006.
English descriptors
- KwdEn :
- Aged, Cyclosporine (pharmacokinetics), Cyclosporine (therapeutic use), Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Monitoring (methods), Female, Follow-Up Studies, Graft Rejection, Graft Survival (drug effects), Humans, Immunosuppressive Agents (pharmacokinetics), Immunosuppressive Agents (therapeutic use), Kidney Failure, Chronic (diagnosis), Kidney Failure, Chronic (immunology), Kidney Failure, Chronic (surgery), Kidney Transplantation (immunology), Kidney Transplantation (methods), Longitudinal Studies, Male, Maximum Tolerated Dose, Middle Aged, Probability, Prospective Studies, Risk Assessment, Sensitivity and Specificity, Time Factors, Transplantation Immunology.
- MESH :
- chemical , pharmacokinetics : Cyclosporine, Immunosuppressive Agents.
- chemical , therapeutic use : Cyclosporine, Immunosuppressive Agents.
- diagnosis : Kidney Failure, Chronic.
- drug effects : Graft Survival.
- immunology : Kidney Failure, Chronic, Kidney Transplantation.
- methods : Drug Monitoring, Kidney Transplantation.
- surgery : Kidney Failure, Chronic.
- Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Graft Rejection, Humans, Longitudinal Studies, Male, Maximum Tolerated Dose, Middle Aged, Probability, Prospective Studies, Risk Assessment, Sensitivity and Specificity, Time Factors, Transplantation Immunology.
Abstract
Therapeutic drug monitoring for cyclosporine microemulsion (CsA-ME) is often performed using either trough levels (C0) or levels at 2 h post-dose (C2). This analysis assessed changes in C0 and C2 and their relationship to CsA-ME dose over time post-transplant in renal transplant patients.
DOI: 10.1093/ndt/gfi113
PubMed: 16204301
Links to Exploration step
pubmed:16204301Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.</title><author><name sortKey="Buchler, Matthias" sort="Buchler, Matthias" uniqKey="Buchler M" first="Matthias" last="Büchler">Matthias Büchler</name><affiliation><nlm:affiliation>Department of Nephrology and Clinical Immunology, C.H.U. Tours, 2 Boulevard Tonnellé 37044 Tours, France, and Royal Prince Alfred Hospital, Sydney, Australia. buchler@med.univ-tours.fr</nlm:affiliation></affiliation></author><author><name sortKey="Chadban, Steve" sort="Chadban, Steve" uniqKey="Chadban S" first="Steve" last="Chadban">Steve Chadban</name></author><author><name sortKey="Cole, Edward" sort="Cole, Edward" uniqKey="Cole E" first="Edward" last="Cole">Edward Cole</name></author><author><name sortKey="Midtvedt, Karsten" sort="Midtvedt, Karsten" uniqKey="Midtvedt K" first="Karsten" last="Midtvedt">Karsten Midtvedt</name></author><author><name sortKey="Thervet, Eric" sort="Thervet, Eric" uniqKey="Thervet E" first="Eric" last="Thervet">Eric Thervet</name></author><author><name sortKey="Prestele, Hans" sort="Prestele, Hans" uniqKey="Prestele H" first="Hans" last="Prestele">Hans Prestele</name></author><author><name sortKey="Keown, Paul" sort="Keown, Paul" uniqKey="Keown P" first="Paul" last="Keown">Paul Keown</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16204301</idno><idno type="pmid">16204301</idno><idno type="doi">10.1093/ndt/gfi113</idno><idno type="wicri:Area/PubMed/Corpus">003C20</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003C20</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.</title><author><name sortKey="Buchler, Matthias" sort="Buchler, Matthias" uniqKey="Buchler M" first="Matthias" last="Büchler">Matthias Büchler</name><affiliation><nlm:affiliation>Department of Nephrology and Clinical Immunology, C.H.U. Tours, 2 Boulevard Tonnellé 37044 Tours, France, and Royal Prince Alfred Hospital, Sydney, Australia. buchler@med.univ-tours.fr</nlm:affiliation></affiliation></author><author><name sortKey="Chadban, Steve" sort="Chadban, Steve" uniqKey="Chadban S" first="Steve" last="Chadban">Steve Chadban</name></author><author><name sortKey="Cole, Edward" sort="Cole, Edward" uniqKey="Cole E" first="Edward" last="Cole">Edward Cole</name></author><author><name sortKey="Midtvedt, Karsten" sort="Midtvedt, Karsten" uniqKey="Midtvedt K" first="Karsten" last="Midtvedt">Karsten Midtvedt</name></author><author><name sortKey="Thervet, Eric" sort="Thervet, Eric" uniqKey="Thervet E" first="Eric" last="Thervet">Eric Thervet</name></author><author><name sortKey="Prestele, Hans" sort="Prestele, Hans" uniqKey="Prestele H" first="Hans" last="Prestele">Hans Prestele</name></author><author><name sortKey="Keown, Paul" sort="Keown, Paul" uniqKey="Keown P" first="Paul" last="Keown">Paul Keown</name></author></analytic><series><title level="j">Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</title><idno type="ISSN">0931-0509</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Cyclosporine (pharmacokinetics)</term><term>Cyclosporine (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Monitoring (methods)</term><term>Female</term><term>Follow-Up Studies</term><term>Graft Rejection</term><term>Graft Survival (drug effects)</term><term>Humans</term><term>Immunosuppressive Agents (pharmacokinetics)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Kidney Failure, Chronic (diagnosis)</term><term>Kidney Failure, Chronic (immunology)</term><term>Kidney Failure, Chronic (surgery)</term><term>Kidney Transplantation (immunology)</term><term>Kidney Transplantation (methods)</term><term>Longitudinal Studies</term><term>Male</term><term>Maximum Tolerated Dose</term><term>Middle Aged</term><term>Probability</term><term>Prospective Studies</term><term>Risk Assessment</term><term>Sensitivity and Specificity</term><term>Time Factors</term><term>Transplantation Immunology</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Cyclosporine</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cyclosporine</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Kidney Failure, Chronic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Graft Survival</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Kidney Failure, Chronic</term><term>Kidney Transplantation</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Monitoring</term><term>Kidney Transplantation</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Kidney Failure, Chronic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Follow-Up Studies</term><term>Graft Rejection</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Maximum Tolerated Dose</term><term>Middle Aged</term><term>Probability</term><term>Prospective Studies</term><term>Risk Assessment</term><term>Sensitivity and Specificity</term><term>Time Factors</term><term>Transplantation Immunology</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Therapeutic drug monitoring for cyclosporine microemulsion (CsA-ME) is often performed using either trough levels (C0) or levels at 2 h post-dose (C2). This analysis assessed changes in C0 and C2 and their relationship to CsA-ME dose over time post-transplant in renal transplant patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16204301</PMID><DateCreated><Year>2005</Year><Month>12</Month><Day>28</Day></DateCreated><DateCompleted><Year>2006</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0931-0509</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</Title><ISOAbbreviation>Nephrol. Dial. Transplant.</ISOAbbreviation></Journal><ArticleTitle>Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.</ArticleTitle><Pagination><MedlinePgn>197-202</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Therapeutic drug monitoring for cyclosporine microemulsion (CsA-ME) is often performed using either trough levels (C0) or levels at 2 h post-dose (C2). This analysis assessed changes in C0 and C2 and their relationship to CsA-ME dose over time post-transplant in renal transplant patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were obtained from MO2ART, a prospective multicentre trial in which CsA-ME dose was adjusted based on C2 level. All 98 patients in whom C0 and C2 were available at day 5, month 3 and month 12 were included, out of 234 who completed the 12 month study. Normalized dose (ND) of CsA-ME, defined as dose per kilogram body weight, was calculated, together with C0/ND, C2/ND and C2/C0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">C0/ND and C2/ND both increased between day 5 and month 3: C0/ND from 33+/-15 to 53+/-24 (ng/ml)/(mg/kg) and C2/ND from 161+/-64 to 248+/-80 (ng/ml)/(mg/kg). Between month 3 and month 12, C2/ND remained stable but C0/ND decreased to 42+/-20 (ng/ml)/(mg/kg) while the C2/C0 ratio increased from 5.2+/-1.9 to 6.5+/-2.3, indicating an acceleration of drug elimination. The inter-individual coefficient of variation was higher for C0/ND than for C2/ND at 3 months (45 vs 32%, P<0.05) and at 12 months (48 vs 31%, P<0.01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CsA clearance accelerates between months 3 and 12 post-transplant, resulting in lower C0 levels for a given exposure (as measured by C2). As a consequence, C0 monitoring may progressively underestimate CsA exposure during the first year post-transplant. C2 monitoring contributes to improved individualized CsA-ME treatment in both the de novo phase and beyond month 3.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Büchler</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Clinical Immunology, C.H.U. Tours, 2 Boulevard Tonnellé 37044 Tours, France, and Royal Prince Alfred Hospital, Sydney, Australia. buchler@med.univ-tours.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chadban</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Midtvedt</LastName><ForeName>Karsten</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Thervet</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Prestele</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Keown</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nephrol Dial Transplant</MedlineTA><NlmUniqueID>8706402</NlmUniqueID><ISSNLinking>0931-0509</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>83HN0GTJ6D</RegistryNumber><NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006085" MajorTopicYN="N">Graft Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020714" MajorTopicYN="N">Maximum Tolerated Dose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014181" MajorTopicYN="Y">Transplantation Immunology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16204301</ArticleId><ArticleId IdType="pii">gfi113</ArticleId><ArticleId IdType="doi">10.1093/ndt/gfi113</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C20 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003C20 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16204301
|texte= Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16204301" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |